Decreased systolic function is a central factor in the pathogenesis of heart failure, yet there are no safe medical therapies to improve cardiac function in patients. Currently available inotropes, such as dobutamine and milrinone, increase cardiac contractility at the expense of increased intracellular concentrations of calcium and cAMP, contributing to increased heart rate, hypotension, arrhythmias, and mortality. These adverse effects are inextricably linked to their inotropic mechanism of action. A new class of pharmacologic agents, cardiac myosin activators, directly targets the kinetics of the myosin head. In vitro studies have demonstrated that these agents increase the rate of effective myosin cross-bridge formation, increasing the ...
Thesis (Ph.D.)--University of Washington, 2014Heart failure is a syndrome characterized by the inabi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second d...
Decreased systolic function is a central factor in the pathogenesis of heart failure, yet there are ...
The Author(s) 2009. This article is published with open access at Springerlink.com Abstract Decrease...
Background Many patients with heart failure remain symptomatic and have a poor prognosis despite exi...
BACKGROUND: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Heart failure is an emerging epidemic in the United States, for example, between 1996 and 2006 the n...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Heart failure became a leading cause of mortality in the past decades with a progressively increasin...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Thesis (Ph.D.)--University of Washington, 2014Heart failure is a syndrome characterized by the inabi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second d...
Decreased systolic function is a central factor in the pathogenesis of heart failure, yet there are ...
The Author(s) 2009. This article is published with open access at Springerlink.com Abstract Decrease...
Background Many patients with heart failure remain symptomatic and have a poor prognosis despite exi...
BACKGROUND: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Heart failure is an emerging epidemic in the United States, for example, between 1996 and 2006 the n...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Heart failure became a leading cause of mortality in the past decades with a progressively increasin...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Thesis (Ph.D.)--University of Washington, 2014Heart failure is a syndrome characterized by the inabi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second d...